Original Articles
19 March 2025
Vol. 19 No. 1 (2025)
Immunohistochemical expression of transient receptor potential vanilloid 1 in World Health Organization grade IV astrocytoma, oral squamous cell carcinoma and bladder carcinoma
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
281
Views
123
Downloads
18
HTML
Authors
Transient receptor potential vanilloid 1 (TRPV1), an ion channel receptor, has been identified to have a variety of functions in cancer, with overexpression associated with tumor suppression as well as promotion, making it an attractive but challenging target for cancer research and therapy. The study aimed to evaluate the immunohistochemical expression of TRPV1 in various cancer grades, including astrocytoma, meningioma, bladder carcinoma, oral squamous cell carcinoma, and normal tissues. A total of 60 patients diagnosed with cancer from King Edward Medical University were studied. All the specimens were prepared for immunohistochemistry by fixing them in formalin and embedding them in paraffin. Tissue consecutive sections were collected on L-lysine-coated slides. To determine the labeling index (i.e., % of labeled cells, LI) for the TRPV1 antibody, two observers independently assessed 10 random non-overlapping fields (×400 total magnification) for each sample and counted manually 100 tumor cells in each field by using an ocular grid. High expression of TRPV1 was seen in the advanced stage of bladder cancer, while decreased expression was seen in low-grade bladder cancer. Very low expression of TRPV1 was seen in breast cancer. Very high expression of TRPV1 was seen in tissue samples of World Health Organization grade 4 astrocytoma. Tissue samples of oral cancer also showed increased expression of TRPV1. Meningioma (negative control) had no expression of TRPV1, and colon cancer (positive control) had high expression. The current study demonstrates distinct patterns of TRPV1 immunohistochemical expression across several cancer types, underlining the context-dependent nature of TRPV1’s function in cancer progression. Further studies should be conducted to further investigate the therapeutic potential of TRPV1.100.
Altmetrics
Downloads
Download data is not yet available.
Citations
Amantini C, Mosca M, Nabissi M, et al. Capsaicin‐induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J Neurochem 2007;102:977-90. DOI: https://doi.org/10.1111/j.1471-4159.2007.04582.x
Nilius B. TRP channels in disease. Biochim Biophys Acta 2007;1772:805-12. DOI: https://doi.org/10.1016/j.bbadis.2007.02.002
Nilius B, Owsianik G. The transient receptor potential family of ion channels. Genome Biol 2011;12:218. DOI: https://doi.org/10.1186/gb-2011-12-3-218
Kaneko Y, Szallasi A. Transient receptor potential (TRP) channels: a clinical perspective. Br J Pharmacol 2014;171:2474-507. DOI: https://doi.org/10.1111/bph.12414
Nilius B, Szallasi A. Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev 2014;66:676-814. DOI: https://doi.org/10.1124/pr.113.008268
Gunthorpe MJ, Benham C, Randall A, Davis JB. The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci 2002;23:183-91. DOI: https://doi.org/10.1016/S0165-6147(02)01999-5
Aghazadeh Tabrizi M, Baraldi PG, Baraldi S, et al. Medicinal chemistry, pharmacology, and clinical implications of TRPV1 receptor antagonists. Med Res Rev 2017;37:936-83. DOI: https://doi.org/10.1002/med.21427
Prevarskaya N, Zhang L, Barritt G. TRP channels in cancer. Biochim Biophys Acta 2007;1772:937-46. DOI: https://doi.org/10.1016/j.bbadis.2007.05.006
Bernardini M, Pla AF, Prevarskaya N, Gkika D. Human transient receptor potential (TRP) channel expression profiling in carcinogenesis. Int J Dev Biol 2015;59:399-406. DOI: https://doi.org/10.1387/ijdb.150232dg
Pla AF, Gkika D. Emerging role of TRP channels in cell migration: from tumor vascularization to metastasis. Front Physiol 2013;4:311. DOI: https://doi.org/10.3389/fphys.2013.00311
Fliniaux I, Germain E, Farfariello V, Prevarskaya N. TRPs and Ca2+ in cell death and survival. Cell Calcium 2018;69:4-18. DOI: https://doi.org/10.1016/j.ceca.2017.07.002
Nabissi M, Morelli MB, Arcella A, et al. Post-transcriptional regulation of 5’-untranslated regions of human transient receptor potential vanilloid type-1 (TRPV-1) channels: role in the survival of glioma patients. Oncotarget 2016;7:81541. DOI: https://doi.org/10.18632/oncotarget.13132
Gautier M, Dhennin-Duthille I, Ay AS, et al. New insights into pharmacological tools to TR (i) P cancer up. Br J Pharmacol 2014;171:2582-92. DOI: https://doi.org/10.1111/bph.12561
Brennan CW, Verhaak RGW, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77. Erratum in: Cell 2014;157:753. DOI: https://doi.org/10.1016/j.cell.2014.04.004
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021;23:1231-51. DOI: https://doi.org/10.1093/neuonc/noab106
Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18:170-86. DOI: https://doi.org/10.1038/s41571-020-00447-z
Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol 2010;99:379-91. DOI: https://doi.org/10.1007/s11060-010-0342-2
Durand A, Labrousse F, Jouvet A, et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 2009;95:367-75. DOI: https://doi.org/10.1007/s11060-009-9934-0
Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 2004;63:275-86. DOI: https://doi.org/10.1093/jnen/63.4.275
Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancerbase 2004;5.
Rafique M, Javed AA. Role of intravenous urography and transabdominal ultrasonography in the diagnosis of bladder carcinoma. Int Braz J Urol 2004;30:185-91. DOI: https://doi.org/10.1590/S1677-55382004000300002
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. DOI: https://doi.org/10.3322/canjclin.55.1.10
Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-24. DOI: https://doi.org/10.1038/39807
Amantini C, Mosca M, Lucciarini R, et al. Distinct thymocyte subsets express the vanilloid receptor VR1 that mediates capsaicin-induced apoptotic cell death. Cell Death Differ 2004;11:1342-56. DOI: https://doi.org/10.1038/sj.cdd.4401506
Birder LA, Kanai AJ, de Groat WC, et al. Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci 2001;98:13396-401. DOI: https://doi.org/10.1073/pnas.231243698
Avelino A, Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn Schmiedebergs Arch Pharmacol 2006;373:287-99. DOI: https://doi.org/10.1007/s00210-006-0073-2
Bodó E, Bíró T, Telek A, et al. A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol 2005;166:985-98. DOI: https://doi.org/10.1016/S0002-9440(10)62320-6
Bodó E, Kovács I, Telek A, et al. Vanilloid receptor-1 (VR1) is widely expressed on various epithelial and mesenchymal cell types of human skin. J Invest Dermatol 2004;123:410-3. DOI: https://doi.org/10.1111/j.0022-202X.2004.23209.x
Marincsák R, Tóth BI, Czifra G, et al. Increased expression of TRPV1 in squamous cell carcinoma of the human tongue. Oral Dis 2009;15:328-35. DOI: https://doi.org/10.1111/j.1601-0825.2009.01526.x
Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000;88:2887. DOI: https://doi.org/10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F
Mehboob R, Tanvir I, Warraich RA, et al. Role of neurotransmitter Substance P in progression of oral squamous cell carcinoma. Pathol Res Pract 2015;211:203-7. DOI: https://doi.org/10.1016/j.prp.2014.09.016
Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H. Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 2003;22:7858-61. DOI: https://doi.org/10.1038/sj.onc.1206895
Caprodossi S, Lucciarini R, Amantini C, et al. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage. Eur Urol 2008;54:612-20. DOI: https://doi.org/10.1016/j.eururo.2007.10.016
Stock K, Kumar J, Synowitz M, et al. Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat Med 2012;18:1232-8. DOI: https://doi.org/10.1038/nm.2827
Tóth A, Blumberg PM, Boczán J. Anandamide and the vanilloid receptor (TRPV1). Vitam Horm 2009;81:389-419. DOI: https://doi.org/10.1016/S0083-6729(09)81015-7
Di Marzo V, Gobbi G, Szallasi A. Brain TRPV1: a depressing TR (i) P down memory lane? Trends Pharmacol Sci 2008;29:594-600. DOI: https://doi.org/10.1016/j.tips.2008.09.004
Maccarrone M, Lorenzon T, Bari M, et al. Anandamide induces apoptosis in human cells via vanilloid receptors: evidence for a protective role of cannabinoid receptors. J Biol Chem 2000;275:31938-45. DOI: https://doi.org/10.1074/jbc.M005722200
Goutsou S, Tsakona C, Polia A, et al. Transient receptor potential vanilloid (TRPV) channel expression in meningiomas: prognostic and predictive significance. Virchows Arch 2019;475:105-14. DOI: https://doi.org/10.1007/s00428-019-02584-y
Shimizu T, Toriumi H, Sato H, et al. Distribution and origin of TRPV1 receptor-containing nerve fibers in the dura mater of rat. Brain Res 2007;1173:84-91. DOI: https://doi.org/10.1016/j.brainres.2007.07.068
Akerman S, Kaube H, Goadsby P. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol 2004;142:1354-60. DOI: https://doi.org/10.1038/sj.bjp.0705896
Amantini C, Ballarini P, Caprodossi S, et al. Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis 2009;30:1320-9. DOI: https://doi.org/10.1093/carcin/bgp138
How to Cite
Immunohistochemical expression of transient receptor potential vanilloid 1 in World Health Organization grade IV astrocytoma, oral squamous cell carcinoma and bladder carcinoma. (2025). Italian Journal of Medicine, 19(1). https://doi.org/10.4081/itjm.2025.1893
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.